In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia***Poster 5 Post-assessment*** Survey

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

2.What is your area of specialty?

Hematology

Oncology

Other (please specify)

3.How many years have you been in practice?

<1

1-10

11-20

>21

4.Please select the option that best describes your practice setting:

5.Of the patients you will see in the next month, about how many will benefit from the information you learned today?

6.After participating in this activity, how confident are you in the management of patients with ALL in your practice?

7.Which of the following is best describes outcomes associated with addition of 1 cycle of nelarabine in adults with ALL based on the UKALL14 study?(Required.)

Improves event-free survival

Increases treatment-related mortality

Not beneficial

Improves overall survival

8.An exploratory analysis of the UKALL14 study found that patients with T-cell ALL with absence of biallelic TCRg deletion (ABD) were associated with which of the following outcomes?(Required.)

Improved response to nelarabine

Improved rate of MRD-negativity after phase 1

Improved rate of MRD-negativity after phase 2

Increased risk of relapse

9.Reduction in treatment intensity by omission of high-dose cytarabine from two cycles of first-line therapy on the GRAAPH 2014 protocol for Philadelphia chromosome positive acute lymphoblastic leukemia is associated with:(Required.)

Decreased overall survival in patients who did not receive a transplant

No change in the incidence of relapse

Improvement in complete response rate

Improvement achievement of MRD negativity at cycle 4

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

10.How committed are you to making changes in your practice based on your participation in this activity?(Required.)

If not committed or do not plan to make changes, please indicate reason

11.Which of the following best describes the impact of this activity on your performance?(Required.)

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

12.Which new strategies/skills/information will you apply to your area of practice?

Plan for comparable complete response and MMR rates in adults with de novo Ph+ ALL regardless of cytarabine administration

Recognize increased risk of relapse when omitting cytarabine from a less intensive chemotherapy regimen in adults with de novo Ph+ ALL

Evaluate the role, or lack thereof, of the addition of nelarabine to standard chemotherapy in adults with T-Cell ALL

Determine the impact of the absence of biallelic TCRg deletion as an independent prognostic factor in adults with T-cell ALL

13.What barriers do you see to making changes in your practice?

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

17.If you indicated that you perceived commercial bias or influence, please describe:

18.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

19.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

20.Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

First & Last Name

Degree/Credentials

ZIP/Postal Code

Country

Email Address

21.I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 Credit^TM.

Yes

No